ONE KENDALL SQUARE, CAMBRIDGE, MA
Michael MacLean Appointed as Class III Director at CAMP4 Therapeutics
Investor Presentation
Material disclosure
CAMP4 Therapeutics Enters Underwriting Agreement for 5 Million Shares
Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Free Writing Prospectus